Price movement over the last 24 hours
Appian Corp vs Teladoc Health Inc — how do they compare? Appian Corp trades at $25.44 (market cap $1.86B), while Teladoc Health Inc trades at $9.24 (market cap $1.68B). The key difference: Appian Corp and Teladoc Health Inc are close in size by market cap, and Teladoc Health Inc is trading nearer its 52-week high, Appian Corp nearer its low. Which is the better fit depends on your goals.
| APPN | TDOC | |
|---|---|---|
Market Cap | $1.86B | $1.68B |
Sector | Technology | Health |
52-Week High | $45.64 | $9.52 |
52-Week Low | $18.72 | $4.47 |
Enterprise Value | $1.95B | $1.96B |
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) trades at $25.36, up 0.48% on the day, with a bullish technical signal from moving averages and a consensus price target of $26.20. The company reported positive net income in 2025 after years of losses, with revenue growing to $726.94M and operating cash flow improving to $62.87M. Recent news highlights focus on AI strategy and enterprise adoption, though the CEO's share sale and negative shareholder equity present mixed signals.
The outlook is cautiously optimistic with revenue growth and cash flow recovery, but risks include high debt levels, negative equity, and intense competition. Analyst sentiment is mixed with a majority Hold rating. The stock offers potential from AI-driven growth but requires monitoring of profitability sustainability and balance sheet health.
Teladoc Health (TDOC) trades at $9.28, up 0.76% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $2.53B in 2025 with a net loss of $200.32M, though losses are narrowing year-over-year. Recent news highlights expansion through the Walmart partnership and ongoing cost-cutting initiatives. Valuation ratios show a P/S of 0.65 and EV/EBITDA of 9.14, suggesting potential undervaluation relative to sales.
Outlook remains cautious despite improving fundamentals; analyst consensus is mixed with 35.7% buy ratings but a $8.75 price target below current levels. Key risks include persistent net losses, competitive pressures in telehealth, and high debt levels. The stock's trajectory hinges on achieving profitability and sustaining growth amid market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →